rasburicase

REMS

Initial management of increased uric acid levels in patients with leukemia, lymphoma, or other malignancies who are being treated with antineoplastics, which are expected to produce hyperuricemia.

Contraindicated in:

Glucose-6–phosphate dehydrogenase (G6PD) deficiency (↑ risk of severe hemolysis);
Previous allergic reaction, hemolysis, or methemoglobinemia from rasburicase;
OB: Pregnancy;
Lactation: Lactation.

Use Cautiously in:

Derm: rash

GI: abdominal pain, constipation, diarrhea, mucositis, nausea, vomiting

Hemat: HEMOLYSIS, METHEMOGLOBINEMIA, neutropenia

Neuro: headache

Resp: respiratory distress

Misc: fever, HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS), sepsis

Drug-drug:

Elitek

An enzyme that promotes the conversion of uric acid to allantoin, an inactive, water-soluble compound.
Produced by recombinant DNA technology.

Therapeutic effects:

Therapeutic Classification: antigout agents, antihyperuricemics

Pharmacologic Classification: enzymes

Absorption: IV administration results in complete bioavailability.

Distribution: Well distributed to tissues.

Metabolism/Excretion: Unknown.

Half-Life: 18 hr.

Fasturtec

(↓ in uric acid)

ROUTE	ONSET	PEAK	DURATION
IV	rapid	unknown	4–24 hr

Inform patient and family of purpose of rasburicase infusion.
Rep: May cause fetal harm. Advise females of reproductive potential to notify health care professional if pregnancy is planned or suspected and to avoid breastfeeding during and for 2 wk after last dose.

ras-BYOOR-i-case